Company Overview
Snapshot
Founded in December 2014 by Hezkiah Tsoory, iRen Medical operates with 1–10 employees. The company has raised $4.76 million across 5 funding rounds from 8 investors. In January 2023, iRen Medical received FDA regulatory clearance for its digital dialysis system.
Business overview
iRen Medical is dedicated to enhancing the lives of dialysis patients by developing portable peritoneal dialysis systems. The company's innovation focuses on providing a safe, patient-friendly, and portable solution that allows individuals to maintain their regular activities while undergoing dialysis. This technology also aims to optimize economic models for clinics, improving service quality and lowering costs. iRen Medical operates within the Health Tech & Life Sciences sector, specifically targeting medical devices, digital healthcare, and patient remote monitoring markets.
Strategic signal
In January 2023, iRen Medical secured FDA regulatory clearance for its digital dialysis system. This clearance is a significant validation of the company's technology, signaling its readiness for market entry and potential to disrupt traditional dialysis treatment by enabling more flexible, home-based care. For investors, this milestone indicates strong progress towards commercialization and addresses a critical need for improved patient quality of life and healthcare efficiency in the nephrology market.
Log in to access full profile ›Company Intelligence Q&A
- What was a key regulatory milestone for iRen Medical?
- In January 2023, iRen Medical received FDA regulatory clearance for its digital dialysis system, a significant step towards commercialization.
- When was iRen Medical founded and by whom?
- iRen Medical was founded in December 2014 by Hezkiah Tsoory, who serves as the CEO.
- What is iRen Medical's primary focus?
- iRen Medical focuses on developing portable peritoneal dialysis systems to free patients from traditional dialysis constraints, enabling them to maintain regular activities while undergoing treatment.